Phase 4 N=116 Oral Challenge in the Pediatric ED
Penicillin Allergy · Pediatric Emergency Medicine
Primary: Number of Oral Amoxicillin Challenge Participants Completing Challenge With Insignificant Adverse Result — 114; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=64 Liposomal Bupivacaine in Rotator Cuff Repair
Rotator Cuff Injury
Primary: Average Postoperative Pain Scores Over a 96 Hour Timeframe — 3.0; 3.5 score on a scale
Phase 4 N=40 Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis
Symptomatic Irreversible Pulpitis
Primary: VAS Scores as Measures of Profoundness of Pulpal Anesthesia — 3.1; 1.2 Score on a scale
Phase 4 N=39 The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy
Anesthesia
Primary: Propofol Requirements With Pre-treatment of Dexmedetomidine With Children Who do Not Receive Dexmedetomidine. — 0.4; 0.23 mg/kg/min
Phase 4 N=101 A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Squamous Cell Carcinoma of Head and Neck
Primary: Objective Response Rate (ORR) — 48.5 Percentage of Participants
Phase 4 N=32 Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia
Primary Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C During Each Treatment — 3.4; -0.7 Percent change from baseline
Phase 4 N=108 SSRI Effects on Depression and Immunity in HIV/AIDS
Depression · HIV · AIDS
Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…
Phase 4 N=25 Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy
Female Urogenital Diseases · Vaginal Atrophy · Postmenopausal Atrophic Vaginitis
Primary: Quantitative Change in Relative Abundance of Lactobacillus Among the Community Composition of Bacteria in the Vagina — 0.07; 0.09; 0.12; 0.04 Relative abundance
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
Phase 4 N=100 CES1 Crossover Trial of Clopidogrel and Ticagrelor
Myocardial Infarction · Thrombosis · Platelet Dysfunction
Primary: Change in Maximal Platelet Aggregation in Response to Clopidogrel — 32.6; 50.8; 35.0 Percent Maximal Platelet Aggregation — p=<0.001
Phase 4 N=26 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01
Phase 4 N=77 Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Healthy
Primary: Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10 — 1.9; -1.5; -3.6; -3.5 milliseconds (msec)
Phase 4 N=267 Simultaneous RZV and aIIV4 Vaccination
Pain · Quality of Life · Injection Site Reaction
Primary: Number of Participants With at Least One Severe (Grade 3) Solicited Local or Systemic Reactogenicity Event After Dose 1 of RZV (SHINGRIX®) in Each Study Group — 115…
Phase 4 N=10 Maraviroc Efficacy for Hepatitis C
Hepatitis C · Human Immunodeficiency Virus
Primary: The Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc — 2035071; 2027648; 2082302; 1216383 International Units/ml — p=0.13
Phase 4 N=56 Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Incidence of Adverse Events During 8 Weeks of Adjunct SPN-812 Treatment — 55.4 percent of subjects